Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma
Conditions
Interventions
Cosibelimab
Cosibelimab + Ublituximab + Bendamustine combination
+1 more
Locations
9
United States
TG Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site
Tucson, Arizona, United States
TG Therapeutics Investigational Trial Site
Fayetteville, Arkansas, United States
TG Therapeutics Investigational Trial Site
Peoria, Illinois, United States
TG Therapeutics Investigational Trial Site
Fort Wayne, Indiana, United States
TG Therapeutics Investigational Trial Site
Fairway, Kansas, United States
Start Date
April 17, 2019
Primary Completion Date
May 3, 2022
Completion Date
August 1, 2022
Last Updated
August 22, 2022
NCT07125872
NCT06936943
NCT06365671
NCT06707259
NCT05472558
NCT05338931
Lead Sponsor
TG Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions